Weighing in on weight-based secukinumab dosing for psoriasis

Deepak M W Balak^{1

2}, Jo Lambert¹

Affiliations

Comment

Deepak M W Balak et al. Br J Dermatol. 2022 Jul.

. 2022 Jul;187(1):10-11.

doi: 10.1111/bjd.21607. Epub 2022 May 16.

Deepak M W Balak^{1

2}, Jo Lambert¹

No abstract available

Comment on

Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial.
Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P, Patekar M, Keefe D. Augustin M, et al. Br J Dermatol. 2022 Jun;186(6):942-954. doi: 10.1111/bjd.20971. Epub 2022 Apr 8. Br J Dermatol. 2022. PMID: 34981829 Clinical Trial.

1. Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet 2021; 397:1301-15.
1. Armstrong AW, Puig L, Joshi A et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol 2020; 156:258-69.
1. Warren RB, Marsden A, Tomenson B et al.; PSORT Consortium and on behalf of the BADBIR Study Group. Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. Br J Dermatol 2019; 180:1069-76.
1. Assan F, Tubach F, Arlegui H et al.; and Psobioteq. First-line biologic therapy and obesity in moderate-to-severe psoriasis: results from the prospective multicenter cohort Psobioteq. Dermatology 2021; 237:338-46.
1. Neema S, Pathania V, Pudasaini N, Subramaniyan R. Optimal biologic dosing in management of obese patients with psoriasis. Indian J Dermatol Venereol Leprol 2021; 87:424-6.